Skip to main content
Caplight Logo









Hillstar Bio

Hillstar Bio

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://hillstarbio.com/

Last Round

Series A

Mar 25, 2025

Total Funding Raised

$67M

Company Overview

Hillstar Bio is a biotechnology company that develops next-generation precision immunology therapies for autoimmune diseases by selectively targeting and depleting pathogenic immune cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

precision immunologybiotechnologyautoimmune diseaseantibody engineeringaxial spondyloarthritisdrug discoveryimmunotherapybiologicsprecision medicinetargeted therapyimmune system resetclinical-stage biotechdrug developmentnext-gen immunologyimmune cell depletion

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hillstar Bio Comparables

Compare Hillstar Bio with similar companies based on industry and business-model similarity.

Hillstar Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Santa Ana Bio
82%
Seismic
74%
AbbVie
68%

Hillstar Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 25, 2025

Key People

Founding team and executive leadership

Lauren Mifflin

COO

Executive Team

Hillstar Bio Investors

Notable investors and investment history

Hillstar Bio investors
InvestorRounds
Droia VenturesSeries A
Frazier Life SciencesSeries A
Novo HoldingsSeries A
LifeArc VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 24, 2025

    Grew 28% QoQ, from 18 to 23 employees.

  • Jun 3, 2025

    Grew 64% QoQ, from 11 to 18 employees.

Hillstar Bio Filings

Explore SEC and related filing metadata, where available.

Hillstar Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Hillstar Bio's valuation, stock price, and market status.

Is Hillstar Bio a public or private company?

Hillstar Bio is a private company.

What is the current stock price of Hillstar Bio?

Hillstar Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Hillstar Bio worth (valuation)?

Valuation information for Hillstar Bio is not publicly available.

Can I buy Hillstar Bio stock?

Hillstar Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Hillstar Bio's last funding round?

Hillstar Bio's most recent funding round was Series A on March 25, 2025.

Who are the main investors in Hillstar Bio?

Key investors in Hillstar Bio include Droia Ventures, Frazier Life Sciences, Novo Holdings.

Will Hillstar Bio IPO soon?

No public IPO plans have been announced for Hillstar Bio.

How can I track Hillstar Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Hillstar Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range15
Year Founded2023
Last FundingMar 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?